Shayan Rayani

Oncology

625 N 6th St
Phoenix, AZ 85004

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations.

Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations.

Journal: Gynecologic oncology reports

Published: July 27, 2025

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Journal: HemaSphere

Published: March 21, 2025

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Journal: JAMA oncology

Published: July 21, 2022

Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases.

Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases.

Journal: Medical oncology (Northwood, London, England)

Published: December 07, 2011

Showing 1-4 of 4

Last Updated: 09/26/2026